Phase
Condition
Dementia
Treatment
Placebo
Peptide PMS-001 Intravenous Injection
Clinical Study ID
Ages 60-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participants must be aged 60 to 80 years (inclusive) at the time of screening,regardless of gender.
Participants must have a Clinical Dementia Rating (CDR) total score > 1, indicatingmoderate to severe dementia.
Participants must provide written informed consent to participate in the study.
Exclusion
Exclusion Criteria:
Presence of other neurological diseases that may cause cognitive decline, such ascerebrovascular disease, encephalitis, brain tumors, traumatic brain injury,epilepsy, Parkinson's disease, etc.
Presence of metabolic diseases that may cause cognitive decline, such as anemia,thyroid dysfunction, folate and vitamin B12 deficiency, etc.
Presence of severe psychiatric disorders, such as major depression.
History of carbon monoxide poisoning.
Presence of acute or severe life-threatening diseases.
Presence of severe visual, auditory, or language impairments that would prevent thecompletion of neuropsychological assessments.
Current use of psychotropic medications or a history of substance abuse.
Individuals with specific allergy histories, or those with a history of allergies totwo or more medications, foods (such as milk), or pollen (excluding untreated,asymptomatic seasonal allergies), or known allergies to components of the study drugor similar agents.
Study Design
Connect with a study center
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai 200025
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.